New drug approval: pembrolizumab as second-line treatment in MSI-H/dMMR endometrial, colorectal, gastric, intestinal and biliary cancers

被引：1
作者：
El-Ghazzi, Nathan [1 ]
Rousseau, Benoit [2 ]
Rodrigues, Manuel [3 ,4 ]
机构：
[1] CHU Clermont Ferrand, Serv Oncol Med, Clermont Ferrand, France
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Equipe Labellisee Ligue Natl Canc, Inserm U830, DNA Repair & Uveal Melanoma DRUM, Paris, France
[4] PSL Res Univ, Inst Curie, Dept Oncol Med, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 01期
关键词：
Mismatch repair deficiency; Endometrial cancer; Gastric cancer; Biliary cancer; Colorectal; Immunotherapy; MICROSATELLITE INSTABILITY;
D O I：
10.1016/j.bulcan.2022.10.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 13
页数：3
相关论文
共 8 条
  • [1] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
    Andre, T.
    Shiu, K-K
    Kim, T. W.
    Jensen, B., V
    Jensen, L. H.
    Punt, C.
    Smith, D.
    Garcia-Carbonero, R.
    Benavides, M.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Bendell, J.
    Le, D. T.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Marinello, P.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2207 - 2218
  • [2] Epidemiology of microsatellite instability across solid neoplasms
    Colle, Raphael
    Cohen, Romain
    [J]. BULLETIN DU CANCER, 2019, 106 (02) : 114 - 118
  • [3] De Jesus C, 2022, B CANC PARIS
  • [4] Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
    Le, Dung T.
    Durham, Jennifer N.
    Smith, Kellie N.
    Wang, Hao
    Bartlett, Bjarne R.
    Aulakh, Laveet K.
    Lu, Steve
    Kemberling, Holly
    Wilt, Cara
    Luber, Brandon S.
    Wong, Fay
    Azad, Nilofer S.
    Rucki, Agnieszka A.
    Laheru, Dan
    Donehower, Ross
    Zaheer, Atif
    Fisher, George A.
    Crocenzi, Todd S.
    Lee, James J.
    Greten, Tim F.
    Duffy, Austin G.
    Ciombor, Kristen K.
    Eyring, Aleksandra D.
    Lam, Bao H.
    Joe, Andrew
    Kang, S. Peter
    Holdhoff, Matthias
    Danilova, Ludmila
    Cope, Leslie
    Meyer, Christian
    Zhou, Shibin
    Goldberg, Richard M.
    Armstrong, Deborah K.
    Bever, Katherine M.
    Fader, Amanda N.
    Taube, Janis
    Housseau, Franck
    Spetzler, David
    Xiao, Nianqing
    Pardoll, Drew M.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Eshleman, James R.
    Vogelstein, Bert
    Anders, Robert A.
    Diaz, Luis A., Jr.
    [J]. SCIENCE, 2017, 357 (6349) : 409 - 413
  • [5] Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105
  • [6] Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
    O'Malley, David M.
    Bariani, Giovanni Mendonca
    Cassier, Philippe A.
    Marabelle, Aurelien
    Hansen, Aaron R.
    Acosta, Ana De Jesus
    Miller, Wilson H., Jr.
    Safra, Tamar
    Italiano, Antoine
    Mileshkin, Linda
    Xu, Lei
    Jin, Fan
    Norwood, Kevin
    Maio, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 752 - 761
  • [7] Pembrolizumab as first-line therapy in microsatellite instability metastatic colorectal cancers
    Pureur, Dimitri
    Rodrigues, Manuel
    Turpin, Anthony
    [J]. BULLETIN DU CANCER, 2021, 108 (03) : 229 - 231
  • [8] Drug Approval: Nivolumab plus ipilimumab for patients with MSI-high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy
    Touati, Ruben
    Cohen, Romain
    [J]. BULLETIN DU CANCER, 2022, 109 (01) : 3 - 4
1